LabGenius

Rounds and research, on one timeline

1. 2026-04-03
   Research

   Level 4 · Tested in the physical world

   LabGenius reports its machine-designed Nectin-4 x CD3 engager kills tumour cells at 0.7 pM and cuts tumour growth by over 90% in mice

   Nectin-4 is already a drug target, and what limits it is the healthy tissue that also carries it; LabGenius's claim is that selectivity can be engineered by how many arms have to bind at once (three to one here, so only dense target expression fires the molecule) rather than by finding a better epitope, and that its own discovery engine is what found the design. This is a conference abstract: mice and cell lines, the company's own assays, no paper, and the dosing interval it proposes rests on preliminary pharmacokinetics.

   Timeline entry →doi.org ↗

2. 2025-12-07
   Research

   Level 4 · Tested in the physical world

   LabGenius' robotic loop built 980 T-cell engagers over five cycles and found ones that killed HER2-high cells at single-digit picomolar and left the low-HER2 model untouched

   On-target damage to healthy tissue is what has kept T-cell engagers out of solid tumours, so a loop optimising the gap between two cell lines aims at the real obstacle. The selectivity figure is a floor, not a measurement: it comes from seeing nothing at the highest dose tested. Everything is cells in a dish, run in-house with two donors per lead, and the paper says these readouts may not match a body. The healthy model is one cell line, T47D, which the paper says carries about as much HER2 as cultured heart muscle cells.

   Timeline entry →doi.org ↗

3. 2024-05-21Series B
   Round

   £35M≈ $44.5M

   For: its ML discovery platform and a wholly owned pipeline of multispecific antibodies for solid tumours

   Models and platform

   Brought total funding to £58M.

   Lead · M Ventures (Merck KGaA) ✓Octopus Ventures ✓LG CorpAtomicoKindred Capital ✓Lux Capital ✓Obvious Ventures

   On the deal: Irina Haivas (Director, Atomico, joins the board); Leila Zegna (Director, Kindred Capital, joins the board); Oliver Hardick (Investor, M Ventures (Merck KGaA), joins the board); Oliver Sims (Investor, Octopus Ventures, joins the board)

   Announced by the company · labgeniustx.com ↗

4. 2020-10Series A
   Round

   $15M

   For: growing its technology platform

   Models and platform

   A $15M extension that brought the Series A to $25M; the first close came in 2019 (Tech.eu, 29 Oct 2020).

   Lead · AtomicoLux Capital ✓Obvious VenturesKindred Capital ✓

   Announced by the company · goodwinlaw.com ↗

5. 2019-10-22Series A
   Round

   $10M

   For: scale the team, widen the discovery platform and start an internal programme of novel antibody fragments

   HiringModels and platform

   First close of the Series A, with CEO James Field on record to TechCrunch; the October 2020 extension below took it to $25M.

   Co-lead · Lux Capital ✓Co-lead · Obvious VenturesFelicis VenturesInovia CapitalAir Street Capital ✓Chris Gibson (Recursion)Patrick Pichette

   On the deal: Chris Gibson (Individual investor); Nan Li (Director, Obvious Ventures, joins the board); Patrick Pichette (Individual investor); Zavain Dar (Director, Lux Capital, joins the board)

   The investor's own page says · Lux Capital: 2019

   Announced by the company · techcrunch.com ↗

6. 2017-11-27Seed
   Round

   $3.6M

   For: open a purpose-built R&D facility in London and keep developing EVA, its AI-driven evolution machine

   Wet labModels and platform

   UKTN gives £2.6M; Tech.eu gives $3.66M.

   Co-lead · Kindred Capital ✓Co-lead · Acequia CapitalBerggruen HoldingsBacked VCBeast VenturesSystem.OneCharlie SonghurstTom McInerney

   On the deal: Charlie Songhurst (Individual investor); Leila Zegna (Founding Partner, Kindred Capital); Tom McInerney (Angel investor)

   The investor's own page says · Kindred Capital: 2017

   Reported by UKTN · uktech.news ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →